Baseline demographic and clinical characteristics (N = 22)
| Characteristic . | Value . |
|---|---|
| Age, median (range), y | 64 (25-71) |
| Sex | |
| Male | 15 (68) |
| Female | 7 (32) |
| ECOG PS at baseline | |
| 0-1 | 12 (55) |
| 2 | 10 (45) |
| Histology | |
| AML | 7 (32) |
| MDS | 13 (59) |
| MDS/MPN | 2 (9) |
| Received antileukemic therapy pre-HCT | 18 (82) |
| Prior venetoclax exposure | 3 (14) |
| Disease/marrow status at time of transplantation | |
| CR/Cri | 12 (55) |
| Marrow CR | 5 (23) |
| Excess blasts | 5 (23) |
| Persistent abnormal cytogenetics at time of allo-HCT | 12 (55) |
| TP53-mutated disease | 12 (55) |
| Donor type | |
| HLA-matched unrelated | 20 (91) |
| HLA-matched related | 2 (9) |
| HCT-CI | |
| 1 | 8 (36) |
| 2-3 | 2 (9) |
| ≥4 | 12 (55) |
| Donor sex | |
| Male | 11 (50) |
| Female | 11 (50) |
| Male recipient and female donor | 7 (32) |
| Characteristic . | Value . |
|---|---|
| Age, median (range), y | 64 (25-71) |
| Sex | |
| Male | 15 (68) |
| Female | 7 (32) |
| ECOG PS at baseline | |
| 0-1 | 12 (55) |
| 2 | 10 (45) |
| Histology | |
| AML | 7 (32) |
| MDS | 13 (59) |
| MDS/MPN | 2 (9) |
| Received antileukemic therapy pre-HCT | 18 (82) |
| Prior venetoclax exposure | 3 (14) |
| Disease/marrow status at time of transplantation | |
| CR/Cri | 12 (55) |
| Marrow CR | 5 (23) |
| Excess blasts | 5 (23) |
| Persistent abnormal cytogenetics at time of allo-HCT | 12 (55) |
| TP53-mutated disease | 12 (55) |
| Donor type | |
| HLA-matched unrelated | 20 (91) |
| HLA-matched related | 2 (9) |
| HCT-CI | |
| 1 | 8 (36) |
| 2-3 | 2 (9) |
| ≥4 | 12 (55) |
| Donor sex | |
| Male | 11 (50) |
| Female | 11 (50) |
| Male recipient and female donor | 7 (32) |
Data are expressed as N (%) unless otherwise indicated.